lomustine has been researched along with Acute Myelogenous Leukemia in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomised multicentre trial a combination of methylprednisolone, vincristine, lomustine, cyclophosphamide and melphalan (MOCCA) was compared with the same regimen omitting methylprednisolone after the first course (COLA) in previously untreated patients with multiple myeloma." | 5.07 | Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group. ( Ala-Harja, K; Almqvist, A; Elonen, E; Hallman, H; Hänninen, A; Ilvonen, M; Isomaa, B; Järvenpää, E; Jouppila, J; Palva, IP, 1993) |
| "Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory." | 2.73 | Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. ( Dastugue, N; Huguet, F; Ifrah, N; Jourdan, E; Perreau, V; Pigneux, A; Reiffers, J; Salmi, LR; Sotto, JJ; Vey, N, 2007) |
| "A study of children in relapse with acute nonlymphocytic leukemia (ANLL) previously maintained in remission with combination chemotherapy including cytosine arabinoside (Ara-C) was undertaken by Children's Cancer Study Group (CCSG) to assess the efficacy of cyclocytidine (Cyclo-C), a depot Ara-C, compared to parenteral Ara-C given every 12 hr." | 2.65 | Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group. ( Baehner, R; Chard, R; Hammond, D; Higgins, G; Movassaghi, N; Pyesmany, A; Sather, H, 1984) |
| "Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "The treatment of acute myeloid leukemia (AML) permits in a population of 25 to 60 years, a complete remission (CR) about 60 to 85% with relapse free survival at 5 years from 45 to 60%." | 1.32 | [Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol]. ( Benchekroun, S; Harif, M; Qachouh, M; Quessar, A, 2003) |
| " Most of these toxic symptoms appeared 8-20 days after the first dose." | 1.28 | Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia. ( Bagot, M; Cordonnier, C; Jais, JP; Kuentz, M; Landais, P; Oksenhendler, E; Roujeau, JC; Vernant, JP, 1989) |
| "14 patients with essential thrombocythemia (ET) and 1 patient with agnogenic myeloid metaplasia received (1-(2-chloroethyl)-cyclohexyl-nitrosourea (CCNU), 80 mg/m2, p." | 1.27 | 1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia. ( Grossi, A; Leoni, F; Rossi Ferrini, P, 1983) |
| "Secondary tumors were noted in 8 out of 675 patients with Hodgkin's disease during remission following treatment." | 1.27 | [Secondary malignant tumors following treatment of Hodgkin's disease]. ( Shishkin, IP, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (57.14) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gourd, E | 1 |
| Bertoli, S | 1 |
| Tavitian, S | 1 |
| Picard, M | 1 |
| Huguet, F | 2 |
| Vergez, F | 1 |
| Delabesse, E | 1 |
| Sarry, A | 1 |
| Bérard, E | 1 |
| Récher, C | 2 |
| Nishikawa, R | 1 |
| Pigneux, A | 2 |
| Harousseau, JL | 1 |
| Witz, F | 1 |
| Sauvezie, M | 1 |
| Bene, MC | 1 |
| Luquet, I | 1 |
| Hunault-Berger, M | 1 |
| Lioure, B | 1 |
| Himberlin, C | 1 |
| Escoffre-Barbe, M | 1 |
| Berthou, C | 1 |
| Lissandre, S | 1 |
| Fegueux, N | 1 |
| Cahn, JY | 1 |
| Jourdan, E | 2 |
| Dreyfus, F | 1 |
| Reiffers, J | 2 |
| Milpied, N | 1 |
| Ifrah, N | 2 |
| Appelbaum, FR | 1 |
| Bruserud, O | 1 |
| Reikvam, H | 1 |
| Kittang, AO | 1 |
| Ahmed, AB | 1 |
| Tvedt, TH | 1 |
| Sjo, M | 1 |
| Hatfield, KJ | 1 |
| Qachouh, M | 1 |
| Quessar, A | 1 |
| Harif, M | 1 |
| Benchekroun, S | 1 |
| Perreau, V | 1 |
| Vey, N | 1 |
| Dastugue, N | 1 |
| Sotto, JJ | 1 |
| Salmi, LR | 1 |
| May, JT | 1 |
| Hsu, SD | 1 |
| Costanzi, JJ | 1 |
| Movassaghi, N | 1 |
| Higgins, G | 1 |
| Pyesmany, A | 1 |
| Baehner, R | 1 |
| Chard, R | 1 |
| Sather, H | 1 |
| Hammond, D | 1 |
| Droz, JP | 1 |
| Kebrat, P | 1 |
| Bayle, C | 1 |
| Ruffié, P | 1 |
| Cukier, J | 1 |
| Amiel, JL | 1 |
| Leoni, F | 1 |
| Grossi, A | 1 |
| Rossi Ferrini, P | 1 |
| Shishkin, IP | 1 |
| Palva, IP | 1 |
| Ala-Harja, K | 1 |
| Almqvist, A | 1 |
| Elonen, E | 1 |
| Hallman, H | 1 |
| Hänninen, A | 1 |
| Ilvonen, M | 1 |
| Isomaa, B | 1 |
| Jouppila, J | 1 |
| Järvenpää, E | 1 |
| Gorin, NC | 2 |
| Stachowiak, J | 2 |
| Hirsch-Marie, F | 1 |
| David, R | 2 |
| Muller, JY | 2 |
| Jullien, AM | 2 |
| Cavalier, J | 2 |
| Salmon, C | 2 |
| Najman, A | 2 |
| Duhamel, G | 2 |
| Hirsch Marie, F | 1 |
| Petit, JC | 1 |
| Leblanc, G | 1 |
| Parlier, Y | 1 |
| Sauter, C | 1 |
| Weil, M | 1 |
| Jacyuillat, CI | 1 |
| Gemon-Auclerc, MF | 1 |
| Chastang, CL | 1 |
| Izrael, V | 1 |
| Boiron, M | 1 |
| Bernard, J | 1 |
| Bernasconi, C | 1 |
| Oksenhendler, E | 1 |
| Landais, P | 1 |
| Cordonnier, C | 1 |
| Kuentz, M | 1 |
| Bagot, M | 1 |
| Jais, JP | 1 |
| Roujeau, JC | 1 |
| Vernant, JP | 1 |
| Vertut-Croquin, A | 1 |
| Brajtburg, J | 1 |
| Medoff, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
| Randomized Prospective Study of Adding Lomustine to Idarubicin and Cytarabine for Induction and Post-remission Chemotherapy in Older Patients With Acute Myeloid Leukaemia, and Feasibility of Allogeneic Transplantation for Patients From 60 to 65 Years Old[NCT00590837] | Phase 3 | 459 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lomustine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Dise | 1989 |
3 trials available for lomustine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; | 2007 |
Evaluation of cyclocytidine in reinduction and maintenance therapy of children with acute nonlymphocytic leukemia previously treated with cytosine arabinoside: a report from Children's Cancer Study Group.
Topics: Adolescent; Adult; Ancitabine; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; | 1984 |
Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leuke | 1993 |
15 other studies available for lomustine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Lomustine in older patients with acute myeloid leukaemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; | 2018 |
Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hemat | 2018 |
Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; | 2010 |
Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia?
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2010 |
[Acute myeloblastic leukemia in adults: evaluation of the AML 06/96 protocol].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2003 |
Acute leukemia following combination chemotherapy for cancer of the lung.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combination; | 1981 |
[Acute myelomonoblastic leukemia in renal cancer treated with CCNU. 4 cases in 29 patients].
Topics: Female; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Lomustine; Male; Nitrosourea Compounds | 1983 |
1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
Topics: Adult; Age Factors; Aged; Alkylating Agents; Busulfan; Female; Humans; Leukemia, Myeloid, Acute; Lom | 1983 |
[Secondary malignant tumors following treatment of Hodgkin's disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
[High dose combination chemotherapy followed by autologous bone marrow transplantation in a case of acute myelocytic leukemia (author's transl)].
Topics: Adult; Bone Marrow Transplantation; Cyclophosphamide; Cytosine; Drug Therapy, Combination; Humans; L | 1977 |
[High dose combination chemotherapy with and without autologous bone marrow transplantation in patients with solid tumors and acute leukemias. Kinetics of recovery of peripheral bloods cells (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; | 1978 |
[The therapy of acute myelogenous leukemia].
Topics: Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, | 1975 |
Acute granulocytic leukemia: treatment of the disease.
Topics: Adolescent; Adult; Age Factors; Blood Transfusion; Child; Child, Preschool; Cyclophosphamide; Cytara | 1976 |
Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Er | 1989 |
Two mechanisms of synergism when amphotericin B is used in combination with actinomycin D or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea against the human promyelocytic leukemia cell line HL-60.
Topics: Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cell Line; Dactinomycin; | 1986 |